BioNexus Gene Lab Corp (BGLC)’s stock has witnessed a price declined of -17.75% from the previous close with its current price standing at $0.22. Its current price is -93.63% under its 52-week high of $3.39 and -6.66% more than its 52-week low of $0.23. Based on the past 30-day period, the stock price is -56.90% below the high and +4.42% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, BGLC’s SMA-200 is $0.4732.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Additionally, it is important to take into account BGLC stock ratios, including its price-to-sales ratio, which is 0.42 for the last tewlve months.BGLC’s price to book ratio for the most recent quarter was 0.41, resulting in an 0.94 price to cash per share for the period.
How does BioNexus Gene Lab Corp (BGLC) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
BioNexus Gene Lab Corp (NASDAQ: BGLC) Ownership Details
I will give a breakdown of the key shareholders in BioNexus Gene Lab Corp (BGLC). Recent figures show that the company’s insiders hold 43.72% of shares. A total of 5 institutional investors hold shares in the company, making 0.88% of its stock and 1.56% of its float.
Sep 30, 2024 , it was reported that the Company’s largest institutional holder is UBS Group AG holding total of 83.31 shares that make 0.46% of the company’s total number of shares and are currently priced at 17936.0.
The securities firm Geode Capital Management, LLC holds 23.68 shares of BGLC, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.13% , and the holding percentage of shares is valued at 5098.0.
An overview of BioNexus Gene Lab Corp’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests BioNexus Gene Lab Corp (BGLC) traded 1,702,365 shares per day, with a moving average of $0.2751 and price change of -0.0721. With the moving average of $0.3225 and a price change of -0.1992, about 731,662 shares changed hands on average over the past 50 days. Finally, BGLC’s 100-day average volume is 595,215 shares, alongside a moving average of $0.3744 and a price change of -0.2679.
